Clinical Trial Update: A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies [Phase 1, Phase 2]

View source ↗

Summary

This Phase 1/2 trial assessed belinostat plus cisplatin, doxorubicin, and cyclophosphamide as first-line therapy for advanced thymic malignancies (thymoma and t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Thymoma

Drugs mentioned

• Belinostat (belinostat)
• CISPLATIN (cisplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Thymoma, Thymic Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2016-11-15